 FLORHAM PARK, N.J., Aug. 18, 2021 GLOBE NEWSWIRE -- Cellectar Biosciences, Inc. NASDAQ: CLRB, a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health NIH Phase II Small Business Innovation Research SBIR grant of approximately 2 Million from the National Cancer Institute NCI. 